

## ► Five Days in May is now a provincial event series!

Educate. Inform. Inspire. Stimulate. Every Tuesday this May, join us to learn about how health research is driving innovation and improvement in BC! [View the full program and register.](#)

Island Health is hosting the following events:

- Quality of Life of Older Adults Living in Nursing Homes: How Can We Measure It and How Can We Improve It?
- Research And Innovations During a Drug Poisoning Emergency: Where are We Now?
- The Latest Developments In Covid-19 Vaccine Research: An Update
- Now What - How Evidence Is Being Used in Post-pandemic Health Service Planning
- Indigenous Cultural Safety, Cultural Humility and Anti-racism: A Journey to a Shared Practice Standard
- Nurse Practitioner Integration into Primary Care in Island Health
- Substance: Drug Checking Research As Service Innovations On Vancouver Island
- The Neil and Susan Manning Cognitive Health Initiative at 5 Years: Creating a Learning Health System for Cognitive Disorders
- BC's Research Response to the COVID-19 Pandemic: The Good, the Bad and the Future
- How Data Infrastructure Is Driving Improved Quality Of Care Across Island Health
- Paddling Together Toward Culturally Safe Emergency Care for Nuu-chah-nulth Elders: Are We On a Good Path?
- Building Research Relationships with Indigenous Communities: An Interactive Workshop
- Celebrating Indigenous Health Graduate Students: A Research Symposium



## CONGRATULATIONS TO THE 2021 EVIDENCE-INTO-PRACTICE *awardees*

The following teams successfully translated knowledge to action to improve care and outcomes:

**Gold:** Brenda Beath

*Preventing diabetic foot amputations through total contact casting in Nanaimo*

**Silver:** Paul Winston


*Ultrasound Guided Diagnostic Nerve Blocks: uniting and revolutionizing the global landscape for spasticity management*

**Bronze:** Karen Baker, Emily Becker, Shannon Ellis

*Mindful sensory regulation in neuro rehabilitation*



# Active Studies in Geo 2 and island-wide



Active and Pending Studies (October 1, 2021 - March 31, 2022)	Principal Investigator	Sites
Opioid use after invasive mechanical ventilation at hospital discharge	Maruyama Anna	RJH
Ceftriaxone as Home Intravenous Therapy for Deep-Seated Methicillin-Sensitive Staphylococcus aureus Infections	Powell Lyle	
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1.	Zulfiqar Muhammad	
BCGP TMA ~ Lifestyle factors and biomarkers of prognosis in colorectal tumours: a pilot study	Bhatti Parveen	
Post Stroke Spasticity Referral Tool: Global Inter-rater Reliability Study	Winston Paul	VGH
Weight Loss Journey	Cornelissen Evelyn	RJH
Denosumab for Osteoblastoma	Charest-Morin Raphael	VGH
Understanding Patterns of Service Utilization for "Medically Hard-to-House" Populations to Optimize Service Delivery	Kuo Alex	
Psychological Impact of COVID-19 Pandemic and Experience: Healthcare Worker Survey	Paterson Theone S. E.	COVID-19
RAFT-AF Extend ~ A Randomized Ablation-based atrial Fibrillation rhythm-control versus rate-control Trial in patients with heart failure and high-burden Atrial Fibrillation Extend	Sterns Laurence	
Hospital Pharmacists and Optimizing Discharge Procedures in Canadian Inpatient Settings	Dahri Karen	
Tumor Tissue Repository/Immune Response to Ovarian Cancer and other gynecological Cancers (BCCA-TTR-IROC) Project and The Ovarian Cancer Immune Epitope Database	Nelson Brad	RJH
PACT-BC: Pharmacy Residency Project ~ Characterizing the Perceived Need for Advanced Clinical Pharmacy Training in BC	Legal Gregory Michael	
Molecular characterization of genitourinary tumor using tissue microarray	Wang Gang	RJH, NRGH, CVH
Sonography Practicums ~ Financial Impact of Sonography Practicums on Hospitals and Clinics in British Columbia	Pidgeon Michelle E.	
Employers' perspective	Jarus-Hakak Avital	
A PHASE III RANDOMIZED, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB (MK-3475, NSC #776864) IN ADDITION TO PACLITAXEL AND CARBOPLATIN FOR MEASURABLE STAGE III OR IVA, STAGE IVB OR RECURRENT ENDOMETRIAL CANCER	Fiorino Leathia Helena	